Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Prurigo nodularis (PN) is a chronic, debilitating dermatologic disease characterised by the presence of highly pruritic nodular lesions. PN highly impacts on patients' quality of life as there are no specific treatments available in Spain. Determine the main value drivers in the treatment of PN...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:305606 |
| Acceso en línea: | https://ddd.uab.cat/record/305606 https://dx.doi.org/urn:doi:10.1002/jvc2.275 |
| Access Level: | acceso abierto |
| Palabra clave: | Decision-making MCDA Multi Criteria Decision Analysis Multi-Criteria Decision Analysis Prurigo nodularis Unmet needs |
| Sumario: | Prurigo nodularis (PN) is a chronic, debilitating dermatologic disease characterised by the presence of highly pruritic nodular lesions. PN highly impacts on patients' quality of life as there are no specific treatments available in Spain. Determine the main value drivers in the treatment of PN in Spain and its main unmet needs using Multi-Criteria Decision Analysis (MCDA). Methods: Literature review to synthesise relevant evidence in an evidence matrix based on the MCDA EVIDEM framework adapted to Spain. A multidisciplinary panel composed of dermatologists, hospital pharmacists and a patient weighted (5-point scale; 0 minimum importance, 5 maximum importance) and scored each criterion included in the framework (from -5 to 5 or 0 to 5 depending on the criterion). Results were discussed in a reflective group session. PN was considered a severe (3.3 ± 0.7) and infrequent (2.0 ± 0.7) disease, with high unmet needs (4.2 ± 0.7) mainly due to the lack of available treatments with specific indication for PN. Current off-label treatments were perceived to have limited efficacy/effectiveness (1.8 ± 1.1), an unfavourable long-term safety profile (2.1 ± 0.9) and low therapeutic impact (1.7 ± 1.1). The measure of patient-reported outcomes (2.7 ± 0.9) was perceived as important, but available tools are not specific. Although the cost of available treatments was not considered high (2.4 ± 1.5), experts agreed that PN is associated with moderately high other medical costs (3.6 ± 1.1) and indirect costs (3.1 ± 0.9). Experts considered that current guidelines and consensus (2.6 ± 0.7) are not clear on severity criteria and treatment algorithm. The quality of evidence (1.4 ± 0.5) of currently used off-label treatments was perceived as low due to a lack of published clinical trials. PN was considered a severe disease associated with relevant unmet needs, including the lack of specific and effective treatments for PN, the lack of consensus on the disease definition, defined severity criteria, prevalence estimations and awareness of PN in Spain. |
|---|